Hardman & Co Research
Hardman & Co Research: Shield Therapeutics (STX): Taking on China
14-Jan-2020 / 07:15 GMT/BST
Hardman & Co Research: Taking on China
Shield Therapeutics (STX) is a commercial-stage company delivering specialty
products that address patients' unmet medical needs, with an initial focus
on treating iron deficiency (ID) with ferric maltol. Recent news that the
FDA had approved this drug for a broad indication opened up a market in the
US currently worth over $1bn p.a. On 8 January, STX announced a development
and commercialisation licence deal in China with Beijing Aosaikang
Pharmaceutical Co (ASK Pharm), whose local expertise should support approval
and deliver strong licensing income in what is the world's second largest
pharmaceuticals market.
Please click on the link below for the full report:
https://www.hardmanandco.com/research/corporate-research/taking-on-china/
[1]
If you are interested in meeting the company, you can register your interest
by clicking on the above link
To contact us: Contact:
Hardman & Co Dr Martin Hall mh@hardmanandco.com
35 New Broad Street dmh@hardmanandco.com
London gp@hardmanandco.com
EC2M 1NH
Dr Dorothea
Hill
www.hardmanandco.com
Dr Gregoire
Pave
Follow us on Twitter
@HardmanandCo +44 20 7194
7622
Hardman & Co Research can still be accessed for free after MiFID II. Please
click here [2] to read the statement.
About Hardman & Co: For the past 25 years Hardman has been producing
specialist research designed to improve investors' understanding of
companies, sectors, industries and investment securities. Our analysts are
highly experienced in their sectors, and have often been highly rated by
professional investors for their knowledge. Our focus is to raise companies'
profiles across the UK and abroad with outstanding research, investor
engagement programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this is
clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed
representative of Capital Markets Strategy Ltd and is authorised and
regulated by the Financial Conduct Authority; our FCA registration number is
600843. Hardman Research Ltd is registered at Companies House with number
8256259.
Our research is provided for the use of the professional investment
community, market counterparties and sophisticated and high net worth
investors as defined in the rules of the regulatory bodies. It is not
intended to be made available to unsophisticated retail investors. Anyone
who is unsure of their categorisation should consult their professional
advisors. This research is neither an offer, nor a solicitation, to buy or
sell any security. Please read the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
952535 14-Jan-2020
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=d4e7f435ea10acc0b000bdc46bd7f184&application_id=952535&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=952535&site_id=vwd&application_name=news
(END) Dow Jones Newswires
January 14, 2020 02:15 ET (07:15 GMT)
© 2020 Dow Jones News
